S

SAB Biotherapeutics Inc
NASDAQ:SABS

Watchlist Manager
SAB Biotherapeutics Inc
NASDAQ:SABS
Watchlist
Price: 3.99 USD 1.01% Market Closed
Market Cap: 190m USD

Wall Street
Price Targets

SABS Price Targets Summary
SAB Biotherapeutics Inc

Wall Street analysts forecast SABS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SABS is 9.01 USD with a low forecast of 5.05 USD and a high forecast of 14.7 USD.

Lowest
Price Target
5.05 USD
27% Upside
Average
Price Target
9.01 USD
126% Upside
Highest
Price Target
14.7 USD
268% Upside
SAB Biotherapeutics Inc Competitors:
Price Targets
AVCT
Avacta Group PLC
31% Upside
ARWR
Arrowhead Pharmaceuticals Inc
7% Downside
BIOCON
Biocon Ltd
11% Upside
ALEC
Alector Inc
49% Upside
EXAS
Exact Sciences Corp
1% Downside
688177
Bio-Thera Solutions Ltd
58% Upside
BBIO
BridgeBio Pharma Inc
12% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
10% Upside

Revenue
Forecast

Revenue Estimate
SAB Biotherapeutics Inc

For the last 3 years the compound annual growth rate for SAB Biotherapeutics Inc's revenue is -72%. The projected CAGR for the next 4 years is 53%.

-72%
Past Growth
53%
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Operating Income
Forecast

Operating Income Estimate
SAB Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
11%
Average Beat

Net Income
Forecast

Net Income Estimate
SAB Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-81%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SABS's stock price target?
Price Target
9.01 USD

According to Wall Street analysts, the average 1-year price target for SABS is 9.01 USD with a low forecast of 5.05 USD and a high forecast of 14.7 USD.

What is SAB Biotherapeutics Inc's Revenue forecast?
Projected CAGR
53%

For the last 3 years the compound annual growth rate for SAB Biotherapeutics Inc's revenue is -72%. The projected CAGR for the next 4 years is 53%.

Back to Top